Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy

Li, Tao; Gui, Yan; Yuan, Tao; Lü, Guoqiang; Bian, Cuidong; Jiang, Qiqi; Huang, Shengsong; Liu, Bo; Wu, Denglong

doi:10.1111/j.1464-410x.2012.11277.x

Cited by 21 publications

(31 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 studies met our inclusion criteria and were finally included for the analysis, involving 11 different tumor types (3 studies of gastric cancer [14–16], 4 of colorectal cancer [17–20], 2 of hepatocellular carcinoma [21, 22], 2 of pancreatic cancer [23, 24], 1 of nasopharyngeal carcinoma [25], 1 of head and neck squamous-cell carcinoma [26], 1 of esophageal cancer [27], 1 of malignant pleural mesothelioma [28], 1 of bladder cancer [29], 1 of prostate cancer [30], and 1 of cervical carcinoma [31]) (Figure 1). A total of 2249 participants were analyzed for the association between HMGB1 expression and disease prognosis, of which 2090 (92.9%) and 1247 (55.4%) ones were respectively included into overall survival (OS) and progression-free survival (PFS) analyses.…”

Section: Resultsmentioning

confidence: 99%

HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review

et al. 2016

View full text Add to dashboard Cite

As there are millions of cancer deaths every year, it is of great value to identify applicable prognostic biomarkers. As an important alarm, the prognostic role of high mobility group box 1 (HMGB1) in cancer remains controversial. We aim to assess the association of HMGB1 expression with prognosis in cancer patients. Systematic literature searches of PubMed, Embase and Web of Science databases were performed for eligible studies of HMGB1 as prognostic factor in cancer. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to evaluate the influence of HMGB1 expression on overall survival (OS) and progression-free survival (PFS) in cancer patients. 18 studies involving 11 different tumor types were included in meta-analysis. HMGB1 overexpression was significantly associated with poorer OS (HR: 1.99; 95% CI, 1.71-2.31) and PFS (HR: 2.26; 95% CI, 1.65-3.10) irrespective of cancer types including gastric cancer, colorectal cancer, hepatocellular carcinoma, pancreatic cancer, nasopharyngeal carcinoma, head and neck squamous-cell carcinoma, esophageal cancer, malignant pleural mesothelioma, bladder cancer, prostate cancer, and cervical carcinoma. Subgroup analyses indicated geographical area and size of studies did not affect the prognostic effects of HMGB1 for OS. Morever, HMGB1 overexpression had a consistent correlation with poorer OS when detected by immunohistochemistry in tissues and enzyme-linked immunosorbent assay in serum, whereas the correlation did not exist by quantitative real-time reverse-transcription polymerase chain reaction in tissues. HMGB1 overexpression is associated with poorer prognosis in patients with various types of cancer, suggesting that it is a prognostic factor and potential biomarker for survival in cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review

et al. 2016

View full text Add to dashboard Cite

show abstract

“…HMGB1 is highly expressed in PCa cells92 and targeting HMGB1 disrupts tumor progression by inhibiting activation of T-cells and reducing infiltration of macrophages which are considered to be key inflammatory cells in promoting variety of cancers including PCa 93. Interestingly, androgen deprivation caused HMG1's secretion in prostatic stromal cells supporting the notion that deprivation therapy may upregulate the expression of HMGB1 leading to either hormone resistance or metastatic disease 94…”

Section: Inflammationmentioning

confidence: 94%

Molecular signaling involving intrinsically disordered proteins in prostate cancer

et al. 2016

View full text Add to dashboard Cite

Investigations on cellular protein interaction networks (PINs) reveal that proteins that constitute hubs in a PIN are notably enriched in Intrinsically Disordered Proteins (IDPs) compared to proteins that constitute edges, highlighting the role of IDPs in signaling pathways. Most IDPs rapidly undergo disorder-to-order transitions upon binding to their biological targets to perform their function. Conformational dynamics enables IDPs to be versatile and to interact with a broad range of interactors under normal physiological conditions where their expression is tightly modulated. IDPs are involved in many cellular processes such as cellular signaling, transcriptional regulation, and splicing; thus, their high-specificity/low-affinity interactions play crucial roles in many human diseases including cancer. Prostate cancer (PCa) is one of the leading causes of cancer-related mortality in men worldwide. Therefore, identifying molecular mechanisms of the oncogenic signaling pathways that are involved in prostate carcinogenesis is crucial. In this review, we focus on the aspects of cellular pathways leading to PCa in which IDPs exert a primary role.

show abstract

“…Recent investigations have tried to apply the improved understanding of tumor cell biology to determine additional tumor characteristics as potential prognostic factors. Such prognostically important factors might help determine the optimal treatment strategy based on the biologic potential of individual tumor (48). On the basis of this study, patients with prostate cancer with low expression of miR-133b or high protein level of RB1CC1 should undergo regular monitoring of serum PSA and clinical symptoms.…”

Section: Discussionmentioning

confidence: 99%

Identification of miR-133b and RB1CC1 as Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer

Wan

Chen

et al. 2014

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

Objective: We aimed to investigate the contribution of microRNA-133b (miR-133b) in prostate cancer cell proliferation, cell cycle, and apoptosis. We also examined expression of miR-133b in prostate cancer tissues, and evaluated the prognostic significance of miR-133b, as well as its target gene RB1CC1 in patients with prostate cancer after radical prostatectomy.Experimental Design: miR-133b mimics (miR-133bm) and anti-miR-133b were transfected into LNCaP and PC-3 cells. CCK-8 was used to look at cell proliferation, flow cytometric analysis was carried out to study cell cycle, and apoptosis was determined by caspase-3 activity. miR-133b expression was assessed by real-time reverse transcription PCR and in situ hybridization in prostatic cell lines and 178 prostate tissue samples, respectively. The protein level of RB1CC1 was examined by Western blot and immunohistochemistry in prostatic cell lines and prostate tissue samples, respectively.Results: Overexpression of miR-133b in LNCaP cells boosted cell proliferation and cell-cycle progression, but inhibited apoptosis; in contrast, miR-133bm promoted cell apoptosis, but suppressed cell proliferation and cell-cycle progression in PC-3 cells. In LNCaP cells, silencing of RB1CC1, a target of miR-133b, inhibited cell apoptosis, and promoted cell-cycle progression. Moreover, miR-133b expression was significantly inversely correlated with RB1CC1 expression in prostate cancer tissues. Multivariate Cox analysis indicated that miR-133b and RB1CC1 might be two independent prognostic factors of biochemical recurrence.Conclusions: miR-133b might enhance tumor-promoting properties in less aggressive LNCaP cells, whereas this miR may act as a tumor suppressor in more aggressive PC-3 cells. miR-133b and RB1CC1 were independent prognostic indicators for prostate cancer. Clin Cancer Res; 20(9); 2312-25. Ó2014 AACR.

show abstract

Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy

Cited by 21 publications

References 31 publications

HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review

HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review

Molecular signaling involving intrinsically disordered proteins in prostate cancer

Identification of miR-133b and RB1CC1 as Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer

Contact Info

Product

Resources

About